KR20190125020A - Natural seasoning composition for improvement of colitis by adding mulberry leaves - Google Patents
Natural seasoning composition for improvement of colitis by adding mulberry leaves Download PDFInfo
- Publication number
- KR20190125020A KR20190125020A KR1020180049231A KR20180049231A KR20190125020A KR 20190125020 A KR20190125020 A KR 20190125020A KR 1020180049231 A KR1020180049231 A KR 1020180049231A KR 20180049231 A KR20180049231 A KR 20180049231A KR 20190125020 A KR20190125020 A KR 20190125020A
- Authority
- KR
- South Korea
- Prior art keywords
- powder
- colitis
- natural seasoning
- weight
- seasoning
- Prior art date
Links
- 235000011194 food seasoning agent Nutrition 0.000 title claims abstract description 82
- 206010009887 colitis Diseases 0.000 title claims abstract description 43
- 240000000249 Morus alba Species 0.000 title claims abstract description 24
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title description 5
- 230000006872 improvement Effects 0.000 title description 4
- 239000000843 powder Substances 0.000 claims abstract description 67
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 7
- 241000238557 Decapoda Species 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 240000000599 Lentinula edodes Species 0.000 claims description 7
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 7
- 229940029982 garlic powder Drugs 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 240000006108 Allium ampeloprasum Species 0.000 claims description 6
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 244000228451 Stevia rebaudiana Species 0.000 claims description 6
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 244000088415 Raphanus sativus Species 0.000 claims 2
- 235000001715 Lentinula edodes Nutrition 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 29
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 29
- 235000019640 taste Nutrition 0.000 abstract description 15
- 239000004278 EU approved seasoning Substances 0.000 abstract description 13
- 230000006698 induction Effects 0.000 abstract description 9
- 239000000796 flavoring agent Substances 0.000 abstract description 4
- 235000019634 flavors Nutrition 0.000 abstract description 4
- 210000002429 large intestine Anatomy 0.000 abstract description 2
- 206010010264 Condition aggravated Diseases 0.000 abstract 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 28
- 238000010171 animal model Methods 0.000 description 11
- 230000009266 disease activity Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 210000000436 anus Anatomy 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 208000016261 weight loss Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000035861 hematochezia Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000220259 Raphanus Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 208000019399 Colonic disease Diseases 0.000 description 4
- 208000027503 bloody stool Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- -1 15g Substances 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229940113720 aminosalicylate Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021148 salty food Nutrition 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Abstract
Description
본 발명은 대장염 개선을 위한 천연 조미료에 관한 것으로, 보다 상세하게는 조미료 첨가물에 대한 궤양성 대장염의 유발 억제 및 개선이 가능한 대장염 개선 천연 조미료에 관한 것이다.The present invention relates to a natural seasoning for improving colitis, and more particularly to a colitis-improving natural seasoning capable of inhibiting and improving the induction of ulcerative colitis for the seasoning additive.
염증성 장질환(Inflammatory bowel disease)은 원인 미상의 만성 염증성 질환으로서, 통상 궤양성 대장염(ulcerative colitis)과 크론병(Crohn's disease)으로 구분된다. 궤양성 대장염은 대장의 점막에 염증과 궤양이 생기며, 주된 증상으로 혈변, 복통을 수반한다. 심한 경우 하루 수회의 혈액과 농을 포함한 대변을 동반하고, 탈수, 빈혈, 발열, 체중감소 등을 초래한다. Inflammatory bowel disease is a chronic inflammatory disease of unknown cause, and is generally classified into ulcerative colitis and Crohn's disease. Ulcerative colitis is an inflammation and ulceration of the mucous membrane of the large intestine, the main symptoms are accompanied by bloody stools, abdominal pain. In severe cases, it is accompanied by feces, including blood and pus, several times a day, leading to dehydration, anemia, fever, and weight loss.
현재까지 밝혀진 병인으로, 흡연/식이 등의 환경적 요인과 유전적 요인 또는 세균 감염 등이 제시되고 있다. 이러한 각 인자들은 단독 또는 복합적으로 관여할 수 있는데 특히, 유전학적 소인이 있는 사람이 이러한 원인에 노출될 시, 장 점막의 염증 및 면역반응이 비정상적으로 증폭되어 만성적인 조직 손상을 일으킬 수 있다. 이러한 특징의 궤양성 대장염은 그 원인과 병태생리가 정확히 밝혀지지 않아 근본적인 치료방법이 없는 상태이다. As etiologies identified to date, environmental factors such as smoking / diet, genetic factors or bacterial infections have been suggested. Each of these factors may be involved alone or in combination. In particular, when a person with genetic predisposition is exposed to these causes, the inflammation and immune response of the intestinal mucosa may be abnormally amplified, resulting in chronic tissue damage. Ulcerative colitis of this characteristic is a state that does not know the exact cause and pathophysiology, there is no fundamental treatment.
궤양성 대장염 치료를 위해 사용되는 치료제는 sulfasalazine, mesalazine 등의 aminosalicylate 제제, 스테로이드 제제가 있으며, 스테로이드 치료에 반응하지 않는 경우, azathioprine, 6-mercaptopurine, Cyclosporin 등의 면역 억제제도 사용되고 있으나, 현재 완치를 기대할 수 있는 약물은 없는 실정이다. 또한, 이러한 약물들의 장기간 투여 시 구역, 구토, 소화불량, 식욕부진, 두통뿐만 아니라 과민 반응에 의한 피부 발진, 발열, 췌장염, 간염, 용혈성 빈혈, 골수 억제 등의 부작용이 초래될 수 있다. Therapeutic agents used for the treatment of ulcerative colitis include aminosalicylate preparations such as sulfasalazine and mesalazine, and steroid preparations.If they do not respond to steroid treatment, immunosuppressants such as azathioprine, 6-mercaptopurine, and cyclosporin are also used. There is no drug that can be. In addition, long-term administration of these drugs may cause side effects such as nausea, vomiting, indigestion, anorexia, headache as well as skin rash due to hypersensitivity reactions, fever, pancreatitis, hepatitis, hemolytic anemia, and bone marrow suppression.
한편, 궤양성 대장염은 유럽이나 미국 등 육식을 주로 하는 서구에 흔한 질병으로, 유럽과 미국의 보고를 분석해 볼 때 발병률이 인구 10만명 당 70-150명 정도로 추정되고 있다. 원래 국내 궤양성 대장염은 드문 질환으로 인식되어 왔는데, 최근에는 우리나라에서도 식생활의 서구화에 따라 발병 빈도가 높아졌으며, 만성적인 대장염을 겪고 있는 환자의 비율 또한 굉장히 증가하고 있는 추세다. Ulcerative colitis is a common disease in carnivorous western countries such as Europe and the United States. According to European and American reports, the incidence rate is estimated to be 70 to 150 per 100,000 population. Originally, domestic ulcerative colitis has been recognized as a rare disease. Recently, in Korea, the incidence has increased due to the westernization of diet, and the proportion of patients suffering from chronic colitis has also increased.
게다가, 한국인들은 서구화된 식습관뿐만 아니라 맵고 짠 음식을 즐기는 식습관 때문에 대장 질환이 심화 되거나 치료 효과가 제한될 수 있다. 또한, 한국 음식들은 대부분 소금, 고춧분말 등의 자극적인 재료를 통해 맛을 내기 때문에 이러한 음식들을 피하는 것에는 한계가 있다. 따라서 조미료 등을 섭취할 때 조미료에 의한 대장염의 유발을 억제할 수 있으며, 대장염 환자들도 대장질환의 심화를 개선할 수 있는 천연 조미료의 개발이 절실히 요구되고 있는 실정이다.In addition, Koreans may not only have westernized eating habits, but also eat spicy and salty foods, which may lead to increased bowel disease or limited therapeutic effects. In addition, most Korean foods are flavored with irritating ingredients such as salt and red pepper powder, so there is a limit to avoiding these foods. Therefore, it is possible to suppress the induction of colitis caused by seasoning when ingesting seasonings, etc., and the development of natural seasonings that can improve the intensification of colon disease in patients with colitis is urgently required.
따라서 본 발명이 해결하고자 하는 과제는 상기한 한계점을 극복하기 위한 것으로, 조미료 첨가물의 섭취에 의한 궤양성 대장염의 유발을 억제하며, 대장질환의 심화를 개선할 수 있는 대장염 개선 천연 조미료를 제공하는 것이다.Therefore, the problem to be solved by the present invention is to overcome the above-mentioned limitations, to suppress the induction of ulcerative colitis by the ingestion of seasoning additives, and to provide a colitis-improved natural seasoning that can improve the intensification of bowel disease .
상기 기술적 과제를 달성하기 위하여,In order to achieve the above technical problem,
본 발명은 뽕잎 분말을 유효성분으로 포함하는 것을 특징으로 하는 대장염 개선 천연 조미료를 제공한다.The present invention provides colitis improved natural seasoning, comprising mulberry leaf powder as an active ingredient.
상술한 바와 같은 본 발명에 따른 대장염 개선 천연 조미료에 있어서, 상기 뽕잎 분말은 건조한 뽕잎을 스테비아 수용액에 침지시킨 후 다시 건조한 후에 분말로 한 것을 사용하는 것이 바람직하다.In the colitis improved natural seasoning according to the present invention as described above, it is preferable to use the mulberry leaf powder as a powder after immersing the dried mulberry leaves in an aqueous solution of stevia and dried again.
상술한 바와 같은 본 발명에 따른 대장염 개선 천연 조미료에 있어서, 상기 천연조미료는 표고버섯 분말, 콩 분말, 새우 분말, 무우 분말, 대파 분말, 마늘 분말, 다시마 분말, 포도당 분말을 더 포함하는 것이 바람직하다.In the colitis-improved natural seasoning according to the present invention as described above, the natural seasoning further comprises shiitake mushroom powder, soybean powder, shrimp powder, radish powder, leek powder, garlic powder, kelp powder, glucose powder. .
상술한 바와 같은 본 발명에 따른 대장염 개선 천연 조미료에 있어서, 상기 뽕잎 분말은 전체 대장염 개선 천연조미료 대비 5~15중량% 함유하는 것이 바람직하다.In the colitis improved natural seasoning according to the present invention as described above, the mulberry leaf powder is preferably contained 5 to 15% by weight compared to the total colitis improved natural seasoning.
상술한 바와 같은 본 발명에 따른 대장염 개선 천연 조미료에 있어서, 전체 대장염 개선 천연조미료 대비 상기 표고버섯 분말은 25~35중량%, 콩 분말은 5~15중량%, 새우 분말은 5~15중량%, 무우 분말은 5~15중량%, 대파 분말은 1~10중량%, 마늘 분말은 1~10중량%, 다시마 분말은 5~15중량%, 포도당 분말은 1~10중량% 함유하는 것이 바람직하다.In the colitis-improved natural seasoning according to the present invention as described above, 25 to 35% by weight of the shiitake mushroom powder, 5 to 15% by weight, 5-15% by weight of shrimp powder, compared to the total colitis-improved natural seasoning, It is preferable to contain 5 to 15% by weight of radish powder, 1 to 10% by weight of leek powder, 1 to 10% by weight of garlic powder, 5 to 15% by weight of kelp powder, and 1 to 10% by weight of glucose powder.
본 발명에 따른 뽕잎을 유효성분으로 포함하는 대장염 개선 천연 조미료는 이를 이용한 음식의 맛과 향이 일반 조미료를 사용했을때 보다 뛰어날 뿐만 아니라 궤양성 대장염의 유발을 억제할 수 있으며, 대장질환의 심화를 개선하는 효과가 있다.Colitis improving natural seasoning comprising mulberry leaves according to the present invention as an active ingredient is not only excellent taste and aroma of food using it, but also inhibit the induction of ulcerative colitis, improve the intensification of colon disease It is effective.
도 1은 DSS로 유발한 궤양성 대장염 동물모델에서 체중감소에 대한 천연 조미료의 효과를 나타내는 그래프이다.
도 2는 DSS로 유발한 궤양성 대장염 동물모델에서 질병활성도에 대한 천연 조미료의 효과를 나타내는 그래프이다.
도 3은 DSS로 유발한 궤양성 대장염 동물모델에서 대장 길이 감소에 대한 천연 조미료의 효과를 나타내는 mouse의 대장 사진이다.
도 4는 DSS로 유발한 궤양성 대장염 동물모델에서 각 실험군의 대장 길이(colon length)를 수치화한 그래프이다.1 is a graph showing the effect of natural seasoning on weight loss in ulcerative colitis animal model induced by DSS.
Figure 2 is a graph showing the effect of natural seasoning on disease activity in ulcerative colitis animal model induced by DSS.
Figure 3 is a photograph of the colon of the mouse showing the effect of natural seasoning on the colon length reduction in ulcerative colitis animal model induced by DSS.
Figure 4 is a graph of the colon length (colon length) of each experimental group in the ulcerative colitis animal model induced by DSS.
이하, 본 발명에 대하여 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 상세히 설명한다.Hereinafter, the present invention will be described in detail so that a person skilled in the art can easily carry out the present invention.
상술한 바와 같이, 현재 조미료는 높은 비율의 나트륨을 포함하고 있으며, 일부 조미료는 매운 성분까지 포함하고 있기 때문에 대장염을 유발하거나 심화시킬 수 있어, 대장염환자는 조미료 섭취에 제한이 있어왔다. 하지만, 음식 섭취 시, 조미료의 섭취 제한은 음식의 맛을 떨어뜨릴 뿐만 아니라 음식 선택에 있어서도 큰 제한을 줄 수 있다. 따라서 음식의 맛과 향을 증가시키며, 조미료 등을 섭취할 때 조미료에 의한 대장염의 유발을 억제하고, 대장염 환자들도 대장질환의 심화를 개선할 수 있는 천연조미료의 개발이 절실히 요구되고 있는 실정이다.As mentioned above, current seasonings contain a high proportion of sodium, and some seasonings contain spicy ingredients, which can cause or intensify colitis, and colitis patients have been limited in their intake of seasonings. However, when ingesting food, ingestion restriction may not only reduce the taste of the food but also give a great restriction in the choice of food. Therefore, there is an urgent need for the development of natural seasonings to increase the taste and aroma of food, to suppress the induction of colitis caused by seasoning when ingesting seasonings, and to improve the intensification of colorectal disease in patients with colitis. .
이에, 본 발명에서는 뽕잎을 유효성분으로 포함하는 대장염 개선 천연 조미료를 제조함으로써 상술한 문제의 해결을 모색하였다. 또한, 뽕잎을 가공 처리하거나 다른 부가 성분을 더 첨가하여 대장염 개선뿐만 아니라 음식의 맛과 향이 일반 조미료를 사용했을때 보다 뛰어날 뿐만 아니라 궤양성 대장염의 유발을 억제할 수 있으며, 대장질환의 심화를 개선하는 효과가 있다.Thus, the present invention sought to solve the above problems by preparing a colitis improved natural seasoning containing mulberry leaves as an active ingredient. In addition, by processing the mulberry leaves or by adding other additional ingredients, not only can the colitis improve, but the taste and aroma of the food is better than that of the general seasoning, and it can suppress the induction of ulcerative colitis and improve the intensification of colon disease. It is effective.
본 발명은 뽕잎 분말을 유효성분으로 포함하는 것을 특징으로 하는 대장염 개선 천연 조미료를 제공하며, 상기 천연조미료는 표고버섯 분말, 콩 분말, 새우 분말, 무우 분말, 대파 분말, 마늘 분말, 다시마 분말, 포도당 분말을 더 포함하는 것이 바람직하다.The present invention provides colitis improved natural seasoning, comprising mulberry leaf powder as an active ingredient, the natural seasoning is shiitake mushroom powder, soybean powder, shrimp powder, radish powder, leek powder, garlic powder, kelp powder, glucose It is preferable to further contain powder.
또한, 뽕잎 분말을 만을 함유하는 경우 쓴 맛으로 천연 조미료로서 호불호가 나타날 수 있어 뽕잎을 분말화하기 전에 건조한 뽕잎을 스테비아를 정제수 녹인 용액에 침지시켜 스테비아를 흡수시킨 다음에 이를 다시 건조하여 분말화한 것을 사용할 수도 있다.In addition, when the mulberry leaf powder contains only a bitter taste may be unfavorable as a natural seasoning, dried mulberry leaves are immersed in a solution of stevia dissolved in purified water before pulverizing the mulberry absorbed stevia and then dried again and powdered You can also use
상기 각종 분말은 열풍건조, 냉풍건조, 진공건조, 원적외선 건조, 팽화건조 등 식품 건조에 흔히 쓰일 수 있는 건조 방법으로 수분을 제거한 후, 분쇄과정을 통해 제조된다.The various powders are prepared through a pulverization process after removing moisture by a drying method that can be commonly used in food drying, such as hot air drying, cold air drying, vacuum drying, far-infrared drying, and expansion drying.
또한, 본 발명의 뽕잎 분말은 전체 대장염 개선 천연조미료 대비 5~15중량% 함유하는 것이 바람직하며, 표고버섯 분말은 25~35중량%, 콩 분말은 5~15중량%, 새우 분말은 5~15중량%, 무우 분말은 5~15중량%, 대파 분말은 1~10중량%, 마늘 분말은 1~10중량%, 다시마 분말은 5~15중량%, 포도당 분말은 1~10중량% 함유하는 것이 바람직하다.In addition, the mulberry leaf powder of the present invention preferably contains 5 to 15% by weight relative to the total colitis improving natural seasoning, shiitake mushroom powder 25 to 35% by weight,
상기 조성비는 반복적인 관능검사 및 실험결과, 가장 바람직한 풍미성을 가지며, 대장염 개선의 효과가 가장 뛰어난 최적의 범위로서 상기 범위를 벗어나게 되면 맛과 향이 떨어지거나 궤양성 대장염의 유발 억제 및 대장질환의 심화 개선의 효과가 미미한 문제가 발생한다.The composition ratio has the most desirable flavor, the result of repeated sensory tests and experiments, the best range of the effect of improving colitis is out of the above range as the taste and aroma or the ulcerative colitis is inhibited and the intensification of colon disease There is a problem that the effect of the improvement is minimal.
이하, 실시예 및 실험예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예 및 실험예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예 및 실험예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. These Examples and Experimental Examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited by these Examples and Experimental Examples according to the gist of the present invention is usually in the art. It will be self-evident for those who have knowledge of.
<< 실시예Example 1: 본원발명의 천연 조미료 구성 및 제조> 1: Composition and preparation of natural seasoning of the present invention>
뽕잎분말 45g으로 조성하여 조미료를 제조하였다.45 g of mulberry leaf powder was prepared to prepare a seasoning.
<실험 예 1: Experimental Example 1: 실시예Example 1에서 제조한 천연 조미료의 DSS로 유도한 궤양성 대장염 개선 효과> Improvement of Ulcerative Colitis Induced by DSS of Natural Seasoning Prepared in 1>
1.1 대장염 동물 모델1.1 Colitis Animal Model
덱스트란 설페이트 소디움(Dextran sulfate sodium, DSS)으로 유도한 대장염 동물모델은 BALB/c 마우스(mouse) 암컷 8주령을 샘타코에서 구입한 후, 동물 실험실에서 1주간 안정, 순화시켜 사용하였다. 한 군을 5마리로 하여, 5% 덱스트란 설페이트 소디움(분자량 36,000-50,000) 수용액을 만들어 안정화된 BALB/c 마우스(mouse)에 7일 동안 물 대신 음용하도록 하여 궤양성 대장염을 유도하였다. 아무 처리도 하지 않은 군을 Blank, DSS를 물 대신 음용한 군을 DSS, DSS로 대장염을 유도하며 본 발명에 따른 천연 조미료를 먹인 군을 DSS + 조미료 첨가군으로 하여 구별하였다. 이때, 천연 조미료 첨가군(실시예 1)은 DSS로 대장염이 유도된 쥐에 100 mg/kg/day의 용량으로 정수된 물에 현탁하여 mouse에 경구 투여하였다.The colitis animal model induced by dextran sulfate sodium (DSS) was used after 8 weeks of BALB / c mouse female was purchased from Samtaco, and then stabilized and purified for 1 week in an animal laboratory. One group of five dogs was prepared with 5% dextran sulfate sodium (molecular weight 36,000-50,000) aqueous solution to induce ulcerative colitis by drinking 7 days instead of water in stabilized BALB / c mice. Blank, DSS group was not treated with water, the group was ingested colitis with DSS, DSS, and the group fed natural seasoning according to the present invention was distinguished as a DSS + seasoning group. At this time, the natural seasoning addition group (Example 1) was suspended orally administered to the mouse purified water at a dose of 100 mg / kg / day in mice induced colitis by DSS.
1.2 동물모델에서 체중변화와 질병활성도 측정1.2 Measurement of Body Weight Change and Disease Activity in Animal Models
각 군의 마우스를 7일간 매일 체중변화를 측정하였다. 질병 유발군의 체중이 정상군에 비해 20%이상 감소하면 해당 mouse는 안락사 시켰으며, 실험 마지막 날(day 7), 질병활성도(disease activity index; DAI)를 측정하였다. 질병활성도는 하기의 표 1과 같이 체중 감소정도, 대변의 경도, 혈변의 유무에 따라 0점에서 4점까지 점수를 부여하여 측정하였다. 대변의 경도는 경단모양으로 잘 형성된 정상 변을 Normal; 정상적인 형태를 형성하지 못하고 질척하지만 항문에 묻지 않는 무른 변을 Loose stool; 액체상으로 항문에 묻는 설사 변을 Diarrehea로 판정하였다. 혈변은 항문 주위에 혈흔이 보이지 않으면 Negative; 항문주위에 혈흔이 보이면 positive; 혈액이 굳지 않은 상채로 항문 주위에 묻어 있으면 Gross bleeding으로 판정하였다. Mice in each group were weighed daily for 7 days. When the weight of the disease-causing group was reduced by more than 20% compared to the normal group, the mice were euthanized. The last day of the experiment (day 7), the disease activity index (DAI) was measured. Disease activity was measured by assigning a score from 0 to 4 points according to the degree of weight loss, the stool hardness, and the presence of bloody stool as shown in Table 1 below. The stool hardness is the normal stool that is well-shaped in the shape of a dandelion, Normal; Loose stool; Diarrehea was determined as a diarrhea stool buried in the anus in the liquid phase. Bloody stool is Negative if no blood is seen around the anus; If blood is seen around the anus, positive; Gross bleeding was determined if the blood was buried around the anus with a stiff solid.
질병활성도는 (몸무게 점수 +대변의 경도 점수 + 혈변 점수)/3 으로 계산하여 본 결과, DSS에 의해 궤양성 대장염을 유발시킨 후, 본 발명에 따른 천연조미료(실시예 1)를 첨가한 군은 DSS에 의해 궤양성 대장염이 유발된 군보다 체중감소가 더 줄어들었으며, 질병활성도가 현저하게 줄어들었음을 확인하였다.The disease activity was calculated as (weight score + stool hardness score + blood stool score) / 3, and as a result, after ulcerative colitis was induced by DSS, the natural seasoning according to the present invention (Example 1) It was confirmed that the weight loss was reduced more and the disease activity was significantly reduced than the group in which ulcerative colitis was induced by DSS.
이로써 본 발명에 따른 천연 조미료는 궤양성 대장염의 유발을 억제할 수 있으며, 대장염 환자들도 대장질환의 심화를 개선할 수 있음을 확인하였다.As a result, the natural seasoning according to the present invention can suppress the induction of ulcerative colitis, and it has been confirmed that colitis patients can improve the intensification of colorectal diseases.
<실시예 2: 본원발명의 천연 조미료 구성 및 제조>Example 2 Composition and Preparation of Natural Seasonings of the Present Invention
뽕잎분말 15g, 표고버섯 분말 60g, 콩 분말 30g, 새우 분말 30g, 무우 분말 30g, 대파 분말 2g, 마늘 분말 2g, 다시마 분말, 15g, 포도당 분말 20g으로 조성하여 조미료를 제조하였다.Mulberry leaf powder 15g, shiitake mushroom powder 60g, soybean powder 30g, shrimp powder 30g, radish powder 30g, leek powder 2g, garlic powder 2g, kelp powder, 15g, glucose powder 20g to prepare a seasoning.
<실험 예 2: Experimental Example 2: 실시예Example 2에서 제조한 천연 조미료의 DSS로 유도한 궤양성 대장염 개선 효과> Improvement of Ulcerative Colitis Induced by DSS of Natural Seasoning Prepared in 2>
1.1 대장염 동물 모델1.1 Colitis Animal Model
덱스트란 설페이트 소디움(Dextran sulfate sodium, DSS)으로 유도한 대장염 동물모델은 BALB/c 마우스(mouse) 암컷 8주령을 샘타코에서 구입한 후, 동물 실험실에서 1주간 안정, 순화시켜 사용하였다. 한 군을 5마리로 하여, 5% 덱스트란 설페이트 소디움(분자량 36,000-50,000) 수용액을 만들어 안정화된 BALB/c 마우스(mouse)에 7일 동안 물 대신 음용하도록 하여 궤양성 대장염을 유도하였다. 아무 처리도 하지 않은 군을 Blank, DSS를 물 대신 음용한 군을 DSS, DSS로 대장염을 유도하며 본 발명에 따른 천연 조미료를 먹인 군을 DSS + 조미료 첨가군으로 하여 구별하였다. 이때, 천연 조미료 첨가군(실시예 2)은 DSS로 대장염이 유도된 쥐에 100 mg/kg/day의 용량으로 정수된 물에 현탁하여 mouse에 경구 투여하였다.The colitis animal model induced by dextran sulfate sodium (DSS) was used after 8 weeks of BALB / c mouse female was purchased from Samtaco, and then stabilized and purified for 1 week in an animal laboratory. One group of five dogs was prepared with 5% dextran sulfate sodium (molecular weight 36,000-50,000) aqueous solution to induce ulcerative colitis by drinking 7 days instead of water in stabilized BALB / c mice. Blank, DSS group was not treated with water, the group was ingested colitis with DSS, DSS, and the group fed natural seasoning according to the present invention was distinguished as a DSS + seasoning group. At this time, the natural seasoning addition group (Example 2) was suspended orally administered to the mouse purified water at a dose of 100 mg / kg / day in mice induced colitis by DSS.
1.2 동물모델에서 체중변화와 질병활성도 측정1.2 Measurement of Body Weight Change and Disease Activity in Animal Models
각 군의 마우스를 7일간 매일 체중변화를 측정하였다(도 1). 질병 유발군의 체중이 정상군에 비해 20%이상 감소하면 해당 mouse는 안락사 시켰으며, 실험 마지막 날(day 7), 질병활성도(disease activity index; DAI)를 측정하였다. 질병활성도는 하기의 표 2와 같이 체중 감소정도, 대변의 경도, 혈변의 유무에 따라 0점에서 4점까지 점수를 부여하여 측정하였다. 대변의 경도는 경단모양으로 잘 형성된 정상 변을 Normal; 정상적인 형태를 형성하지 못하고 질척하지만 항문에 묻지 않는 무른 변을 Loose stool; 액체상으로 항문에 묻는 설사 변을 Diarrehea로 판정하였다. 혈변은 항문 주위에 혈흔이 보이지 않으면 Negative; 항문주위에 혈흔이 보이면 positive; 혈액이 굳지 않은 상채로 항문 주위에 묻어 있으면 Gross bleeding으로 판정하였다. 질병활성도는 (몸무게 점수 +대변의 경도 점수 + 혈변 점수)/3 으로 계산하여 도 2에 나타내었다.Mice in each group were measured for daily weight changes for 7 days (FIG. 1). When the weight of the disease-causing group was reduced by more than 20% compared to the normal group, the mice were euthanized. The last day of the experiment (day 7), the disease activity index (DAI) was measured. Disease activity was measured by assigning a score from 0 to 4 points according to the weight loss degree, hardness of stool, blood presence or absence as shown in Table 2 below. The stool hardness is the normal stool that is well-shaped in the shape of a dandelion, Normal; Loose stool; Diarrehea was determined as a diarrhea stool buried in the anus in the liquid phase. Bloody stool is Negative if no blood is seen around the anus; If blood is seen around the anus, positive; Gross bleeding was determined if the blood was buried around the anus with a stiff solid. Disease activity is shown in Figure 2 calculated by (weight score + hardness score of feces + blood stool score) / 3.
그 결과, DSS에 의해 궤양성 대장염을 유발시킨 후, 본 발명에 따른 천연조미료(실시예 2)를 첨가한 군은 DSS에 의해 궤양성 대장염이 유발된 군보다 체중감소가 더 줄어들었으며, 질병활성도가 현저하게 줄어들었음을 확인하였다.As a result, after inducing ulcerative colitis by DSS, the group added with the natural seasoning according to the present invention (Example 2) had less weight loss than the group in which ulcerative colitis was induced by DSS, disease activity It was confirmed that the significantly reduced.
1.3 동물모델에서 대장 길이(colon length) 측정1.3 Colon length measurement in animal models
실험 종료 후, mouse를 디에틸에테르를 흡입하여 마취시켰다. 개복하여 대장을 적출한 후, 각 군별 대장 길이를 측정하고 대표 Image를 도 3에 나타내었다. 또한, 각 군별로 맹장에서부터 항문까지의 길이를 모두 측정한 후, 평균값을 구하고 통계처리를 통해 조미료 첨가군의 궤양성 대장염 억제 정도를 확인하였다(도 4). After the end of the experiment, mice were anesthetized by inhaling diethyl ether. After the colon was opened and the colon was removed, the colon length of each group was measured and a representative image is shown in FIG. In addition, after measuring the length from the cecum to the anus for each group, the average value was obtained and the degree of inhibition of ulcerative colitis of the seasoning added group through statistical processing (Fig. 4).
그 결과, DSS에 의해 궤양성 대장염을 유발시킨 후, 본 발명에 따른 천연조미료(실시예 2)를 첨가한 군은 DSS에 의해 궤양성 대장염이 유발된 군보다 대장길이(colon length)가 더 길어졌음을 확인하였다. As a result, after inducing ulcerative colitis by DSS, the group added with natural seasoning according to the present invention (Example 2) has a longer colon length than the group in which ulcerative colitis was induced by DSS. It was confirmed that it was lost.
이로써 본 발명에 따른 천연 조미료는 궤양성 대장염의 유발을 억제할 수 있으며, 대장염 환자들도 대장질환의 심화를 개선할 수 있음을 확인하였다.As a result, the natural seasoning according to the present invention can suppress the induction of ulcerative colitis, and it has been confirmed that colitis patients can improve the intensification of colorectal diseases.
<실험 예 3: Experimental Example 3: 실시예Example 2에서 제조한 천연 조미료의 관능검사> Sensory Evaluation of Natural Seasonings Prepared in 2>
실시예 2에서 제조한 천연 조미료에 대한 관능검사를 실시하였다. 칼국수 110g에 실험구로 실시예 2에서 제조한 천연 조미료를 5g 첨가하였고, 대조구로 시판중인 조미료(상품명: 다시다)를 5g 첨가하였다.The sensory test was performed on the natural seasoning prepared in Example 2. 5 g of the natural seasoning prepared in Example 2 was added to 110 g of kalguksu, and 5 g of a commercial seasoning (trade name: Dashi) was added as a control.
성인 남녀 각각 25명씩 50명을 선정하여 실험구과 대조구의 칼국수를 블라인드 테스트법으로 먹게한 후, 맛, 향 및 맛의 전반적인 만족도를 최고점수 5점, 최저점수 0점으로 하여 관능검사를 실시하였다. Twenty-five adult men and women were selected to have the kalguksu in the experimental and control groups by blind test method, and the sensory test was conducted with the highest score of 5 and the lowest score of 0 for the overall satisfaction of taste, aroma and taste.
맛, 향, 전반적인 만족도에 따른 평균점수를 하기 표 3에 나타내었다.The average score according to taste, aroma, and overall satisfaction is shown in Table 3 below.
그 결과, 실시예 2에서 제조한 천연 조미료는 기존의 시판 중인 조미료(다시다)보다 음식의 맛과 향을 더욱 좋게 함을 확인하였다.As a result, it was confirmed that the natural seasoning prepared in Example 2 improves the taste and aroma of food more than conventional commercial seasonings (again).
<< 실시예Example 3: 본원발명의 천연 조미료 구성 및 제조> 3: Composition and preparation of natural seasoning of the present invention>
건조한 뽕잎을 정제수에 스테비아를 20중량%로 녹인 용액에 30분 동안 침지시킨 후에 이를 다시 건조하여 분쇄하여 뽕잎분말 45g으로 조성하여 조미료를 제조하였다.The dried mulberry leaves were immersed in a solution of stevia dissolved in 20% by weight in purified water for 30 minutes, then dried again and ground to form a mulberry leaf powder 45g to prepare a seasoning.
<실험 예 4: Experimental Example 4: 실시예Example 3에서 제조한 천연 조미료의 관능검사> Sensory Evaluation of Natural Seasonings Prepared in 3>
실시예 3에서 제조한 천연 조미료에 대한 관능검사를 실시하였다. 칼국수 110g에 실험구로 실시예 3에서 제조한 천연 조미료를 5g 첨가하였고, 대조구로 시판중인 조미료(상품명: 다시다)를 5g 첨가하였다.The sensory test was performed on the natural seasoning prepared in Example 3. 5 g of the natural seasoning prepared in Example 3 was added to 110 g of kalguksu, and 5 g of a commercial seasoning (trade name: Dashi) was added as a control.
성인 남녀 각각 25명씩 50명을 선정하여 실험구과 대조구의 칼국수를 블라인드 테스트법으로 먹게한 후, 맛, 향 및 맛의 전반적인 만족도를 최고점수 5점, 최저점수 0점으로 하여 관능검사를 실시하였다. Twenty-five adult men and women were selected to have the kalguksu in the experimental and control groups by blind test method, and the sensory test was conducted with the highest score of 5 and the lowest score of 0 for the overall satisfaction of taste, aroma and taste.
맛, 향, 전반적인 만족도에 따른 평균점수를 하기 표 4에 나타내었다.The average score according to taste, aroma, and overall satisfaction is shown in Table 4 below.
그 결과, 실시예 3에서 제조한 천연 조미료는 기존의 시판 중인 조미료(다시다)보다 음식의 맛과 향을 더욱 좋게 함을 확인하였다.As a result, it was confirmed that the natural seasoning prepared in Example 3 improves the taste and aroma of food more than conventional commercial seasonings (again).
이상에서 살펴본 바와 같이 본 발명에 따른 천연 조미료는 뽕잎 분말로 이루어져 대장염을 완화할 수 있는 유용한 조미료이며, 또한 본 발명은 뽕잎 분말 함유 조미료의 기호성을 더욱 향상시키기 위하여 스테비아 처리 및 다른 조미 성분의 부가하였는데, 그 효과 또한 상기 시험예에서 충분히 입증이 되어 본 발명은 대장염 개선과 맛과 향을 향상시키는 조미료로서의 역할 모두를 만족할 수 있는 천연 조미료를 제공한다.As described above, the natural seasoning according to the present invention comprises a mulberry leaf powder is a useful seasoning to relieve colitis, and the present invention was added to the stevia treatment and other seasoning ingredients to further improve the palatability of the mulberry leaf powder-containing seasoning. , The effect is also well demonstrated in the above test example, the present invention provides a natural seasoning that can satisfy both the role as a seasoning to improve colitis and improve taste and aroma.
Claims (5)
Colitis improving natural seasoning, comprising mulberry leaf powder as an active ingredient.
The method of claim 1, wherein the mulberry leaf powder is a colitis improved natural seasoning, characterized in that the dried mulberry leaves are immersed in a stevia aqueous solution and then dried again to a powder.
The colitis improving natural seasoning according to claim 1 or 2, wherein the mulberry leaf powder contains 5 to 15% by weight of the total colitis improving natural seasoning.
According to claim 3, The natural seasoning is colitis improved natural seasoning, characterized in that it further comprises shiitake powder, soybean powder, shrimp powder, radish powder, leek powder, garlic powder, kelp powder, glucose powder.
The method according to claim 4, wherein the shiitake mushroom powder is 25-35% by weight, 5-15% by weight of soybean powder, 5-15% by weight of shrimp powder, 5-15% by weight of radish powder, and leek compared to natural seasoning. 1 to 10% by weight of powder, 1 to 10% by weight of garlic powder, 5 to 15% by weight of kelp powder, 1 to 10% by weight of glucose powder, characterized in that colitis improved natural seasoning.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180049231A KR20190125020A (en) | 2018-04-27 | 2018-04-27 | Natural seasoning composition for improvement of colitis by adding mulberry leaves |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180049231A KR20190125020A (en) | 2018-04-27 | 2018-04-27 | Natural seasoning composition for improvement of colitis by adding mulberry leaves |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190125020A true KR20190125020A (en) | 2019-11-06 |
Family
ID=68541995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180049231A KR20190125020A (en) | 2018-04-27 | 2018-04-27 | Natural seasoning composition for improvement of colitis by adding mulberry leaves |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20190125020A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200069238A (en) | 2018-12-05 | 2020-06-16 | 주식회사 보타메디 | Compositions containing phlorotannin for enhancing the flavor of food |
| WO2023186181A1 (en) * | 2022-04-01 | 2023-10-05 | 北京五和博澳药业股份有限公司 | Application of mulberry extract in preparation of drug for treating ulcerative colitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101145751B1 (en) | 2008-10-16 | 2012-05-16 | 유한회사한풍제약 | Composition for treating or preventing inflammatory bowel disease |
-
2018
- 2018-04-27 KR KR1020180049231A patent/KR20190125020A/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101145751B1 (en) | 2008-10-16 | 2012-05-16 | 유한회사한풍제약 | Composition for treating or preventing inflammatory bowel disease |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200069238A (en) | 2018-12-05 | 2020-06-16 | 주식회사 보타메디 | Compositions containing phlorotannin for enhancing the flavor of food |
| WO2023186181A1 (en) * | 2022-04-01 | 2023-10-05 | 北京五和博澳药业股份有限公司 | Application of mulberry extract in preparation of drug for treating ulcerative colitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4913968B2 (en) | Methods for treating malignancies and viral infections using dietary supplements and improving immune function | |
| Song et al. | Anti-colitic effects of kanjangs (fermented soy sauce and sesame sauce) in dextran sulfate sodium-induced colitis in mice | |
| JP6360972B2 (en) | Composition for preventing or ameliorating non-alcoholic fatty liver disease comprising white pea extract as an active ingredient | |
| JP2011098896A (en) | Composition for reducing uric acid value | |
| KR20190125020A (en) | Natural seasoning composition for improvement of colitis by adding mulberry leaves | |
| JP2006055074A (en) | Hop extract-containing composition | |
| CN106615818A (en) | Piglet premixed feed for relieving diarrhea with astringents and preparation method thereof | |
| US9895421B2 (en) | Pharmaceutical composition having preventative or treatment effect on inflammatory bowel diseases | |
| KR101951403B1 (en) | A composition for preventing or treating inflammatory bowel disease comprising mistletoe extract as an active ingredient | |
| JPWO2016104429A1 (en) | Cancer cell growth inhibitory composition and cancer cell growth inhibitory method | |
| WO2019106851A1 (en) | Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (naflad) and/or non-alcoholic steatohepatitis (nash), and/or hepatic steatosis | |
| KR101396553B1 (en) | Composition for improvement, relief and treatment of colitis comprising peucedanum japonicum thunberg leaf as active componet | |
| JP4610730B2 (en) | Composition for calcium supplementation | |
| JP2005023008A (en) | Internal liquid medicine composition containing vitamin b group | |
| JPH11147828A (en) | Absorption inhibitor against cholesterol and lipid | |
| JP3461628B2 (en) | healthy food | |
| US20190160138A1 (en) | Dietary supplement for gluten reaction | |
| TWI832945B (en) | Composition for suppressing increase in blood glucose level and suppressing increase in blood triglyceride | |
| Hidayat et al. | Potency of Turmeric (Curcuma longa L.) and Temulawak (Curcuma xanthorrhiza Roxb.) in Handling Coronavirus Disease 2019 (COVID-19) | |
| JP2005350419A (en) | Antiallergic composition | |
| JPH0363229A (en) | Medicine composition having antitumor action | |
| JP2000072683A (en) | Health adjuvant | |
| KR20210058030A (en) | A Method of Manufacture of Beverage Compounds with Herb Sweet rice drink and L-Arginine as the main ingredients | |
| JP2019199433A (en) | Gastric mucosa protective agent | |
| JP2020105138A (en) | Alcohol metabolism improver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E90F | Notification of reason for final refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) |